98%
921
2 minutes
20
Recurrent upper-tract urothelial carcinoma (UTUC) following radical cystectomy is an uncommon but clinically significant occurrence. We present the case of a 48-year-old man with a history of muscle-invasive bladder cancer (pT2N0M0) treated with radical cystectomy and Bricker ileal conduit diversion. He remained recurrence-free on structured surveillance for 42 months before developing isolated, painless stomal bleeding without associated systemic symptoms. Cross-sectional imaging revealed a 1.6 cm enhancing mass at the left uretero-enteric anastomosis with mild proximal hydroureteronephrosis, and PET-CT confirmed localized hypermetabolic activity without nodal or distant spread. The patient underwent laparoscopic radical nephroureterectomy with en-bloc excision of the distal ureter and limited conduit revision. Histopathology confirmed high-grade invasive UTUC (pT2) with lympho-vascular invasion, negative surgical margins, and a negative hilar node. He subsequently received four cycles of adjuvant gemcitabine-cisplatin (GC) chemotherapy. 18 months postoperatively, the patient remains asymptomatic with preserved renal function and no evidence of radiological recurrence. This case highlights the importance of considering upper-tract recurrence in the differential diagnosis of conduit bleeding. It supports timely cross-sectional imaging and oncologic resection as key steps in achieving long-term disease control.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377796 | PMC |
http://dx.doi.org/10.7759/cureus.88821 | DOI Listing |
Curr Opin Urol
September 2025
Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Purpose Of Review: Nonmuscle-invasive bladder cancer (NMIBC) patients with BCG-unresponsive disease have limited treatment options beyond radical cystectomy. With ongoing BCG shortages and the urgent need for bladder-preserving alternatives, this review examines the emerging role of oncolytic virus therapy as a novel intravesical treatment approach for this challenging patient population.
Recent Findings: Multiple oncolytic viral platforms have entered clinical trials for NMIBC treatment, demonstrating promising efficacy and safety profiles.
Front Med (Lausanne)
August 2025
Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
A 73-year-old male was admitted to our department with complaints of upper abdominal distension, accompanied by dull pain and belching for more than 10 days. Gastroscopy revealed a broad-based raised lesion, approximately 1.0 cm in diameter, on the anterior wall of the gastric body, with a central star-shaped depression, erosion, and surrounding congestion.
View Article and Find Full Text PDFMed Pr
September 2025
Uniwersytet Medyczny w Lublinie, Lublin (Wydział Lekarski).
Bladder cancer is one of the most commonly diagnosed cancers, especially in older people. Bladder cancer belongs to urothelial carcinomas, which can also occur in other parts of the urinary tract (also at the same time). The most common symptom of bladder cancer is hematuria.
View Article and Find Full Text PDFJ Egypt Natl Canc Inst
September 2025
National Cancer Institute of Cairo University, Giza, Egypt.
Objectives: To balance the extended functional urinary voiding and morbidity outcomes amid Ileal W and Y-shaped contrasted to spherical ileocoecal (IC) orthotopic bladders subsequent prostate-sparing radical cystectomy (PRC) versus standard radical cystoprostatectomy (RC).
Material And Methods: Two hundred eight male bladder cancer patients were grouped into 98 RC followed by 43-W, 31-Y, and 23-IC in comparison to 110 PRC followed by 35-W, 37-Y, and 38-IC. The functional voiding outcomes were determined by detailed patients' interview and urodynamic studies (UDS).
Urol Oncol
September 2025
Department of Urology, Columbia University Irving Medical Center, New York, NY.
Objective: To evaluate the role of Rescue BCG in the treatment of BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC), in order to inform clinical decision-making especially when access to alternative therapies is limited.
Methods: From an institutional database, patients who met the criteria of BCG-unresponsive NMIBC between 2002 and 2023 were identified and sorted into 2 cohorts: those who received additional BCG therapy immediately after BCG-unresponsive designation and those who received alternative treatments such as intravesical chemotherapy and radical cystectomy. Primary endpoint was progression-free survival (PFS).